Share on StockTwits

Zeltiq Aesthetics (NASDAQ:ZLTQ) VP Carl Lamm unloaded 4,580 shares of the company’s stock on the open market in a transaction that occurred on Wednesday, July 30th. The stock was sold at an average price of $20.23, for a total value of $92,653.40. Following the completion of the sale, the vice president now directly owns 24,724 shares in the company, valued at approximately $500,167. The sale was disclosed in a document filed with the SEC, which is available at this link.

Zeltiq Aesthetics (NASDAQ:ZLTQ) traded down 5.15% on Thursday, hitting $20.24. The stock had a trading volume of 1,857,808 shares. Zeltiq Aesthetics has a 52 week low of $6.67 and a 52 week high of $24.79. The stock has a 50-day moving average of $15.94 and a 200-day moving average of $17.84. The company’s market cap is $757.8 million.

Zeltiq Aesthetics (NASDAQ:ZLTQ) last announced its earnings results on Tuesday, July 29th. The company reported $0.07 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.13) by $0.20. The company had revenue of $47.10 million for the quarter, compared to the consensus estimate of $34.93 million. Zeltiq Aesthetics’s revenue was up 79.1% compared to the same quarter last year. On average, analysts predict that Zeltiq Aesthetics will post $-0.39 earnings per share for the current fiscal year.

ZLTQ has been the subject of a number of recent research reports. Analysts at Leerink Swann raised their price target on shares of Zeltiq Aesthetics from $26.00 to $27.00 in a research note on Thursday. Separately, analysts at Maxim Group raised their price target on shares of Zeltiq Aesthetics from $25.00 to $30.00 in a research note on Wednesday. They now have a “buy” rating on the stock. Finally, analysts at Cantor Fitzgerald reiterated a “positive” rating on shares of Zeltiq Aesthetics in a research note on Monday, May 5th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $24.26.

Zeltiq Aesthetics, Inc operates as a medical device development company. It engages in the design, development, and commercialization of non-invasive procedures for the reduction of unwanted fat tissue.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.